Aster DM Healthcare acquired 4,50,89,995 equity shares in its subsidiary, Aster DM Super-Specialty Hospital (Sarjapur) Private Limited, for a total cash consideration of ₹45,08,99,950 on June 18, 2026. The acquisition, executed through a rights issue at ₹10 per share, consolidates 100% ownership of the Sarjapur Entity. The investment is intended for general corporate purposes of the subsidiary, which operates within the healthcare services sector.

The Sarjapur Entity was incorporated on July 21, 2025, in Bengaluru, Karnataka, with the objective of setting up and operating healthcare services. As the entity is yet to commence business, turnover figures are not applicable. The authorized share capital stands at ₹153,55,00,000, comprising equity shares and compulsorily convertible preference shares, while the paid-up share capital prior to this transaction was ₹50,10,00,000.

The transaction falls within the ambit of related party transactions as the Sarjapur Entity is a wholly owned subsidiary of Aster DM Healthcare. However, the deal is exempt from related party transaction provisions under Regulation 23(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as it involves a holding company and its wholly owned subsidiary. The transaction was conducted at an arm’s length basis.

No governmental or regulatory approvals were required for the acquisition. The allotment of the 4,50,89,995 equity shares was completed on June 18, 2026. Apart from the holding company, the promoter or promoter group companies do not hold any interest in the Sarjapur Entity.

Details of Acquisition

Aster DM Healthcare Limited has initiated the process to secure central government approval for the appointment of Dr. Mandayapurath Azad Moopen as Executive Director. The company published a notice to members on June 5, 2026, pursuant to Section 201 of the Companies Act, 2013, outlining its intention to apply for the necessary sanctions. This regulatory step is required to formalize the directorship and associated remuneration for the specified period.

The appointment, which covers the period from April 15, 2026 to May 28, 2026, was previously approved by the Board of Directors on March 10, 2026. Shareholders subsequently endorsed the proposal through a postal ballot conducted via electronic voting on April 12, 2026. The company is now moving to satisfy the final regulatory requirements under Sections 196, 197, and 201 of the Companies Act, read with Schedule V.

Key Details of the Appointment

The notice specifies that the application to the Central Government encompasses both the appointment of Dr. Moopen and the payment of his remuneration. The terms and conditions governing this role were established by the Board and ratified by the shareholders earlier this year.

The publication of this notice in newspapers such as the Financial Express and AndhraJyothy serves as a formal intimation to the members regarding the company's compliance with the statutory provisions. The company has also made the information available on its official website.